TaiMed Biologics Cash Flow Reinvestment Rate

Latest as of June 2026: 4.93x

TaiMed Biologics cash flow reinvestment rate. TaiMed Biologics (4147) has a Cash Flow Reinvestment Rate of 4.93x as of June 2026, reinvesting NT$290.16 Million (capex NT$26.35 Million plus investments NT$263.81 Million) from operating cash flow of NT$58.88 Million. See 4147 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Reinvestment Rate

4.93x

(Capex + Investments) / Operating CF

Total Reinvested

NT$290.16 Million

Capex + Investments

Operating Cash Flow

NT$58.88 Million

TWD

Capital Expenditures

NT$26.35 Million

TWD

Cash Flow Reinvestment Rate of TaiMed Biologics (2025–2025)

Cash flow reinvestment rate of TaiMed Biologics from 2025 to 2025. Historical reinvestment intensity for TaiMed Biologics across 1 annual periods. Explore 4147 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

TaiMed Biologics Cash Flow Reinvestment Rate by Year (2025–2025)

TaiMed Biologics cash flow reinvestment rate by year from 2025 to 2025. Year-by-year capital reinvestment analysis for TaiMed Biologics. For the full cash flow conversion analysis, see TaiMed Biologics cash flow conversion.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2025	1.04x	NT$199.46 Million	NT$191.14 Million	NT$22.77 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow